Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, before the U.S. market open. A live webcast with management will follow at 8:00 a.m. Eastern Time and will be posted on the company’s Investor Relations website approximately two hours later. Participants are advised to register at least 15 minutes before the webcast for a timely connection.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced on January 22, 2026 that it granted inducement equity awards on January 15, 2026 to 40 new non‑executive employees under its 2025 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants total options to purchase 3,049 shares and 13,145 time‑based restricted stock units (RSUs). Options carry an exercise price of $495.88, equal to the closing price on the grant date. Option vesting: 25% on the first anniversary, then 6.25% each quarterly anniversary thereafter. RSUs vest in four equal annual installments on the first through fourth anniversaries. All vesting is subject to continued employment as of each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted an inducement equity award on Jan 15, 2026 to Rita Thakkar upon her hiring as Chief Accounting Officer. The award, approved under Nasdaq Listing Rule 5635(c)(4), comprises 2,398 time-based restricted stock units and options to purchase 1,826 shares with an exercise price of $495.88 per share (equal to the closing price on the grant date). Options vest 25% after one year and 6.25% each quarter thereafter; RSUs vest in four equal annual installments. All vesting is conditioned on continued employment as of each vesting date.
Madrigal (NASDAQ:MDGL) announced an exclusive global license from Pfizer for ervogastat, a Phase 2 oral DGAT-2 inhibitor, plus rights to two additional early-stage MASH assets. Madrigal paid an upfront $50 million (recorded in Q4 2025) and is eligible for milestone payments and royalties. Ervogastat showed Phase 2 MRI-PDFF results (72% ≥30% liver fat reduction; 61% ≥50%), and Madrigal plans a 2026 drug‑interaction study with Rezdiffra and FDA consultation on a Phase 2 combination trial.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced on December 18, 2025 that it granted inducement equity awards on December 15, 2025 to four new non-executive employees under its 2025 Inducement Plan.
The awards totalled 1,394 time-based restricted stock units, approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). All RSUs vest in four equal annual installments on each of the first through fourth anniversaries of the grant date, and vesting is subject to each employee’s continued employment on the applicable vesting date.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 PM PST. The presentation will be broadcast live and accessible via the company's Investor Relations Events and Presentations page, with a replay available after the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced equity inducement awards granted on December 1, 2025 to 24 new non-executive employees under its 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The grants comprise options to purchase 4,099 shares and 14,630 time-based restricted stock units. Options carry an exercise price of $579.45 per share, equal to the closing price on the grant date.
Options vest 25% after one year, then 6.25% each quarterly anniversary thereafter; RSUs vest in four equal annual installments. All vesting is conditional on continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on November 15, 2025 to three new non-executive employees under its 2025 Inducement Plan. The independent Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants total 2,125 time-based restricted stock units (RSUs), vesting in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in three investor conference fireside chats in late November and early December 2025. Presentations and live webcasts are scheduled as follows: Jefferies Global Healthcare Conference in London on Nov 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET); Evercore Healthcare Conference on Dec 2, 2025 at 4:15 P.M. ET; and Piper Sandler Healthcare Conference on Dec 3, 2025 at 1:30 P.M. ET. All fireside chats will be webcast live and can be accessed via Madrigal’s Investor Relations Events page.
Madrigal (NASDAQ: MDGL) reported two-year Phase 3 MAESTRO-NAFLD-1 data showing that Rezdiffra (resmetirom) produced statistically significant improvements in multiple noninvasive imaging tests and biomarkers in patients with compensated MASH cirrhosis (F4c).
Key findings: n=122 (113 completed two years), subgroup with platelets <100,000/µL (n=30) showed VCTE reductions of -7.9 kPa (platelets <100k) and -6.4 kPa (platelets >100k), two-thirds of patients shifted to lower Baveno CSPH risk by Year 2, and pooled QoL improvements were seen across MAESTRO (n=1,323). Treatment interruptions (mean 77–111 days) led to reversible loss of benefit. Rezdiffra is approved for noncirrhotic MASH (F2–F3); safety in cirrhosis is not established.